The Pediatric HIV Working Group Home Page

The Pediatric HIV Working Group is part of the HIV and AIDS Malignancy Branch (HAMB) of the National Cancer Institute, which conducts translational research aimed at the development of therapy for HIV infection, AIDS malignancies, and other HIV-related diseases in children, adolescents, and adults.

Within HAMB, the Pediatric HIV Working Group (PHWG), which was formerly part of the Pediatric Branch, conducts clinical trials and provides family-centered care for HIV-infected children and families who participate in those trials. Since 1986 the PHWG has taken a leading role in implementing Phase I studies of new agents or new combinations of agents for the treatment of children with HIV infection. AZT, ddI, ddC, 3TC, and ritonavir were first given to children in Phase I studies conducted by the PHWG. Data generated from these studies led to FDA appproval for use of these agents in children.

The Pediatric HIV Clinical Research Program is located in the Clinical Center on the main campus of the National Institutes of Health (NIH) in Bethesda, Maryland. NIH is the world's premier biomedical research institution and is an agency of the U.S. Department of Health and Human Services.

Please read the disclaimers regarding the material presented in the Pediatric HIV Working Group Home Page.

To learn more about us please select any of the following:

• Frequently asked questions (FAQS)
• Current protocols open for enrollment
• How to refer a patient
• The Children's Inn at NIH
• Other clinical research programs on the NIH campus for children with HIV and cancer NCI, Pediatric Oncology Branch

Other sites for pediatric clinical trials information

• PACTG
• ACTIS
• AIDS treatment Data Network

Other pediatric HIV sites

• Pediatric AIDS Foundation
• Pediatric HIV/AIDS Links